Alvir, JM, Lieberman, JA, Safferman, AZ, et al. (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New England Journal of Medicine, 329: 162–7.
Andrès, E, Mourot, R, Keller, O, et al. (2014) Drug-induced agranulocytosis in elderly patients: diagnosis and management of life-threatening infections and septic shock. Journal of Infectious Diseases & Therapy, 2: 191.
Banerjee, A, Mbamalu, D, Ebrahimi, S, et al. (2011) The prevalence of polypharmacy in elderly attenders to an emergency department: a problem with a need for an effective solution. International Journal of Emergency Medicine, 4: 22.
Barak, Y, Wittenberg, N, Naor, S, et al. (1999) Clozapine in elderly psychiatric patients: tolerability, safety and efficacy. Comprehensive Psychiatry, 40: 320–5.
Cancelli, I (2010) Anticholinergic drugs increase the risk of cognitive decline and dementia in older people. Evidence-based Mental Health, 13: 44.
Capasso, RM, Lineberry, TW, Bostwick, JM, et al. (2008) Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950–2005. Schizophrenia Research, 98: 287–9.
Crooks, J, O'Malley, K, Stevenson, IH (1976) Pharmacokinetics in the elderly. Clinical Pharmacokinetics, 1: 280–96.
Curran, S, Bullock, R (2005) Practical Old Age Psychopharmacology. Radcliffe Publishing.
Gallagher, P, Ryan, C, Byrne, S, et al. (2008) STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 46: 72–83.
Gareri, P, De Fazio, P, Russo, E, et al. (2008) The safety of clozapine in the elderly. Expert Opinion on Drug Safety, 7: 525–38.
Guenette, MD, Powell, V, Johnston, K, et al. (2013) Risk of neutropenia in a clozapine-treated elderly population. Schizophrenia Research, 148(1–3): 183–5.
Hack, N, Fayad, SM, Monari, EH, et al. (2014) An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. PLoS ONE, 9(3): e91545.
Herbert, Y, Meltzer, MD, Alphs, L (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry, 60: 82–91.
Joint Formulary Committee (2017) British National Formulary (74th edn). BMJ Group and Pharmaceutical Press.
Kane, J, Honigfeld, G, Singer, J (1988) Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45: 789–96.
Klein, C, Gordon, J, Pollack, L, et al. (2003) Clozapine in Parkinson's disease psychosis: 5 year follow-up review. Clinical Neuropharmacology, 26: 8–11.
Kohen, I, Lester, P, Lam, S (2010) Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole. Neuropsychiatric Disease and Treatment, 6: 47–58.
Kuzuhara, S (2001) Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. Journal of Neurology, 248(suppl 3): III28–31.
Lally, J, Brook, J, Dixon, T, et al. (2014) Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series. Therapeutic Advances Psychopharmacology, 4: 117–22.
Lally, J, Docherty, MJ, MacCabe, JH (2016) Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database of Systematic Reviews, 6: CD011566 (doi: 10.1002/14651858.CD011566.pub2).
Lamberti, JS, Olson, D, Crilly, JF, et al. (2006) Prevalence of the metabolic syndrome among patients receiving clozapine. American Journal of Psychiatry, 163: 1273–6.
Lieberman, JA, Stroup, TS, McEvoy, JP, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353: 1209–23.
Naranjo, CA, Hermann, N, Mittmann, N (1995) Recent advances in geriatric psychopharmacology. Drugs and Aging, 7: 184–202.
National Institute for Health and Care Excellence (2014) Psychosis and Schizophrenia in Adults: Prevention and Management (Clinical Guideline CG178). NICE.
National Institute for Health and Care Excellence (2017) Parkinson's Disease in Adults (NICE Guideline NG71). NICE.
Paranthaman, R, Baldwin, R (2006) Survey of clozapine use by consultant old age psychiatrists. Psychatric Bulletin, 30: 410–2.
Parkinson Study Group (1999) Low-dose of clozapine for the treatment of drug-induced psychosis in Parkinson's disease. New England Journal of Medicine, 340: 757–63.
Pollack, P, Tison, F, Rascol, O (2004) Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. Journal of Neurology, Neurosurgery & Psychiatry, 75: 689–95.
Praharaj, SK, Arora, M, Gandorta, S (2006) Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology, 185: 265–73.
Pridan, S, Swartz, M, Baruch, Y, et al. (2015) Effectiveness and safety of clozapine in elderly patient with chronic resistant schizophrenia. International Psychogeriatrics, 27: 131–4.
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, et al. (2011) A new monitoring protocol for clozapine induced myocarditis bases on an analysis of 75 cases and 94 controls. Australian and New Zealand Journal of Psychiatry, 45: 458–65.
Sajatovic, M, Ramirez, LF, Garver, D, et al. (1998) Clozapine therapy for older veterans. Psychiatric Services, 49: 340–4.
Salzman, C (2005) Clinical Geriatric Psychopharmacology (4th edn). Lippincott Williams & Wilkins.
Sanyal, S, Van Tol, HH (1997) Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. Journal of Psychiatric Research, 31: 219–32.
Taylor, D, Patron, C, Kapur, S (2015) The Maudsley Prescribing Guidelines in Psychiatry (12th edn). Wiley-Blackwell.
Tiihonen, J, Lönnqvist, J, Wahlbeck, K, et al. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet, 374: 620–27.
Tune, LE, Salzman, C (2003) Schizophrenia in late life. Psychiatric Clinics of North America, 26: 103–13.